Quadrant Capital Group LLC Purchases 2,024 Shares of Smith & Nephew plc (NYSE:SNN)

Quadrant Capital Group LLC raised its position in shares of Smith & Nephew plc (NYSE:SNN) by 37.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,431 shares of the medical equipment provider’s stock after purchasing an additional 2,024 shares during the period. Quadrant Capital Group LLC’s holdings in Smith & Nephew were worth $183,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Securities Inc. raised its position in Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 691 shares in the last quarter. R Squared Ltd bought a new stake in Smith & Nephew during the 4th quarter valued at $41,000. National Bank of Canada FI raised its position in Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 446 shares in the last quarter. Hara Capital LLC raised its position in Smith & Nephew by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 1,957 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Smith & Nephew by 31.8% during the 4th quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock valued at $73,000 after purchasing an additional 718 shares in the last quarter. 25.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

SNN has been the subject of several recent research reports. Canaccord Genuity Group reissued a “hold” rating and issued a $27.00 price target on shares of Smith & Nephew in a research report on Monday, March 17th. UBS Group lowered Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 12th. Finally, StockNews.com raised Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $27.00.

Smith & Nephew Trading Up 3.5 %

Shares of NYSE:SNN opened at $25.84 on Thursday. The business’s 50-day moving average is $27.38 and its 200 day moving average is $26.68. Smith & Nephew plc has a 1 year low of $23.65 and a 1 year high of $31.72. The firm has a market capitalization of $11.30 billion, a P/E ratio of 11.96, a P/E/G ratio of 1.26 and a beta of 0.71. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Smith & Nephew Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be given a dividend of $0.447 per share. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. This represents a yield of 2.5%. The ex-dividend date is Friday, March 28th. Smith & Nephew’s dividend payout ratio is currently 41.20%.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.